BHC
Price
$6.06
Change
-$0.12 (-1.94%)
Updated
Nov 19, 04:59 PM (EDT)
Capitalization
2.29B
98 days until earnings call
Intraday BUY SELL Signals
TKPHF
Price
$28.09
Change
+$1.65 (+6.24%)
Updated
Nov 12 closing price
Capitalization
44.4B
Intraday BUY SELL Signals
Interact to see
Advertisement

BHC vs TKPHF

Header iconBHC vs TKPHF Comparison
Open Charts BHC vs TKPHFBanner chart's image
Bausch Health Companies
Price$6.06
Change-$0.12 (-1.94%)
Volume$16.98K
Capitalization2.29B
Takeda Pharmaceutical
Price$28.09
Change+$1.65 (+6.24%)
Volume$25.31K
Capitalization44.4B
BHC vs TKPHF Comparison Chart in %
BHC
Daily Signal:
Gain/Loss:
TKPHF
Daily Signal:
Gain/Loss:
View a ticker or compare two or three
VS
BHC vs. TKPHF commentary
Nov 20, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is BHC is a Hold and TKPHF is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Nov 20, 2025
Stock price -- (BHC: $6.18 vs. TKPHF: $28.09)
Brand notoriety: BHC: Notable vs. TKPHF: Not notable
Both companies represent the Pharmaceuticals: Generic industry
Current volume relative to the 65-day Moving Average: BHC: 74% vs. TKPHF: 104%
Market capitalization -- BHC: $2.29B vs. TKPHF: $44.4B
BHC [@Pharmaceuticals: Generic] is valued at $2.29B. TKPHF’s [@Pharmaceuticals: Generic] market capitalization is $44.4B. The market cap for tickers in the [@Pharmaceuticals: Generic] industry ranges from $63.66B to $0. The average market capitalization across the [@Pharmaceuticals: Generic] industry is $4.12B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

BHC’s FA Score shows that 0 FA rating(s) are green whileTKPHF’s FA Score has 2 green FA rating(s).

  • BHC’s FA Score: 0 green, 5 red.
  • TKPHF’s FA Score: 2 green, 3 red.
According to our system of comparison, TKPHF is a better buy in the long-term than BHC.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

BHC’s TA Score shows that 4 TA indicator(s) are bullish while TKPHF’s TA Score has 4 bullish TA indicator(s).

  • BHC’s TA Score: 4 bullish, 6 bearish.
  • TKPHF’s TA Score: 4 bullish, 5 bearish.
According to our system of comparison, both BHC and TKPHF are a bad buy in the short-term.

Price Growth

BHC (@Pharmaceuticals: Generic) experienced а -9.25% price change this week, while TKPHF (@Pharmaceuticals: Generic) price change was +6.25% for the same time period.

The average weekly price growth across all stocks in the @Pharmaceuticals: Generic industry was -3.86%. For the same industry, the average monthly price growth was -6.64%, and the average quarterly price growth was +28.04%.

Reported Earning Dates

BHC is expected to report earnings on Feb 25, 2026.

Industries' Descriptions

@Pharmaceuticals: Generic (-3.86% weekly)

A generic drug contains the same chemical substance as a drug that was originally protected by patents. Generic drugs are generally sold at cheaper price points, compared to name-brand pharmaceuticals, after patents for the more expensive drugs lapse. The generic drug industry has created a major market, thanks to the lower pricing. According to the Center for Justice and Democracy at New York Law School, 80 percent of all drugs prescribed are generic, and generic drugs are chosen 94 percent of the time when they are available. But their manufacturers must be able to prove to the FDA that they can be effective substitutes for the original drugs. Some of the major generic drug makers include Zoetis, Inc., Allergan plc and Mylan N.V.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
TKPHF($44.4B) has a higher market cap than BHC($2.29B). TKPHF has higher P/E ratio than BHC: TKPHF (211.18) vs BHC (6.37). TKPHF YTD gains are higher at: 5.028 vs. BHC (-23.325). TKPHF has higher annual earnings (EBITDA): 1.04T vs. BHC (3.29B). TKPHF has more cash in the bank: 740B vs. BHC (1.31B). BHC has less debt than TKPHF: BHC (21B) vs TKPHF (4.65T). TKPHF has higher revenues than BHC: TKPHF (4.42T) vs BHC (10B).
BHCTKPHFBHC / TKPHF
Capitalization2.29B44.4B5%
EBITDA3.29B1.04T0%
Gain YTD-23.3255.028-464%
P/E Ratio6.37211.183%
Revenue10B4.42T0%
Total Cash1.31B740B0%
Total Debt21B4.65T0%
FUNDAMENTALS RATINGS
BHC vs TKPHF: Fundamental Ratings
BHC
TKPHF
OUTLOOK RATING
1..100
7040
VALUATION
overvalued / fair valued / undervalued
1..100
36
Fair valued
7
Undervalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
10087
PRICE GROWTH RATING
1..100
5857
P/E GROWTH RATING
1..100
982
SEASONALITY SCORE
1..100
n/a50

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

TKPHF's Valuation (7) in the null industry is in the same range as BHC (36) in the Pharmaceuticals Other industry. This means that TKPHF’s stock grew similarly to BHC’s over the last 12 months.

TKPHF's Profit vs Risk Rating (100) in the null industry is in the same range as BHC (100) in the Pharmaceuticals Other industry. This means that TKPHF’s stock grew similarly to BHC’s over the last 12 months.

TKPHF's SMR Rating (87) in the null industry is in the same range as BHC (100) in the Pharmaceuticals Other industry. This means that TKPHF’s stock grew similarly to BHC’s over the last 12 months.

TKPHF's Price Growth Rating (57) in the null industry is in the same range as BHC (58) in the Pharmaceuticals Other industry. This means that TKPHF’s stock grew similarly to BHC’s over the last 12 months.

TKPHF's P/E Growth Rating (2) in the null industry is significantly better than the same rating for BHC (98) in the Pharmaceuticals Other industry. This means that TKPHF’s stock grew significantly faster than BHC’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
BHCTKPHF
RSI
ODDS (%)
Bullish Trend 2 days ago
63%
Bullish Trend 2 days ago
41%
Stochastic
ODDS (%)
Bullish Trend 2 days ago
77%
Bearish Trend 2 days ago
53%
Momentum
ODDS (%)
Bearish Trend 2 days ago
82%
Bullish Trend 2 days ago
49%
MACD
ODDS (%)
Bearish Trend 2 days ago
80%
Bullish Trend 2 days ago
46%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
78%
Bullish Trend 2 days ago
45%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
67%
Bearish Trend 2 days ago
44%
Advances
ODDS (%)
Bullish Trend 8 days ago
74%
N/A
Declines
ODDS (%)
Bearish Trend 3 days ago
78%
N/A
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
82%
Bullish Trend 2 days ago
56%
Aroon
ODDS (%)
Bearish Trend 2 days ago
76%
Bearish Trend 2 days ago
50%
View a ticker or compare two or three
Interact to see
Advertisement
BHC
Daily Signal:
Gain/Loss:
TKPHF
Daily Signal:
Gain/Loss:
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
MWOHX63.96N/A
N/A
MFS Global Growth R3
TLVAX23.19N/A
N/A
Timothy Plan Large/Mid Cap Value A
RSMOX23.44N/A
N/A
Victory RS Mid Cap Growth A
LSGRX32.65-0.22
-0.67%
Loomis Sayles Growth Y
INGIX20.62-0.17
-0.82%
Voya US Stock Index Port I

BHC and

Correlation & Price change

A.I.dvisor indicates that over the last year, BHC has been loosely correlated with AMRX. These tickers have moved in lockstep 39% of the time. This A.I.-generated data suggests there is some statistical probability that if BHC jumps, then AMRX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To BHC
1D Price
Change %
BHC100%
+0.82%
AMRX - BHC
39%
Loosely correlated
-0.04%
AMPH - BHC
35%
Loosely correlated
-0.46%
VTRS - BHC
31%
Poorly correlated
+0.47%
NBIX - BHC
28%
Poorly correlated
-3.44%
TEVA - BHC
26%
Poorly correlated
+1.02%
More

TKPHF and

Correlation & Price change

A.I.dvisor tells us that TKPHF and TAK have been poorly correlated (+27% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that TKPHF and TAK's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To TKPHF
1D Price
Change %
TKPHF100%
N/A
TAK - TKPHF
27%
Poorly correlated
-0.50%
TEVJF - TKPHF
17%
Poorly correlated
N/A
ZTS - TKPHF
16%
Poorly correlated
-0.56%
BHC - TKPHF
15%
Poorly correlated
+0.82%
QNTM - TKPHF
13%
Poorly correlated
-6.10%
More